We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

183 hedge funds and large institutions have $701M invested in Meridian Bioscience Inc in 2019 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 80 increasing their positions, 46 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,212% more call options, than puts

Call options by funds: $1.99M | Put options by funds: $60K

74% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 46

2% more capital invested

Capital invested by funds: $690M → $701M (+$11.4M)

4% less funds holding

Funds holding: 191183 (-8)

28% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 25

Holders
183
Holders Change
-8
Holders Change %
-4.19%
% of All Funds
3.96%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
80
Reduced
46
Closed
25
Calls
$1.99M
Puts
$60K
Net Calls
+$1.93M
Net Calls Change
-$151K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$111M +$354K +21,261 +0.3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$80.3M +$2.42M +145,216 +3%
BCM
3
Brown Capital Management
Maryland
$63.8M -$543K -32,655 -0.9%
Renaissance Technologies
4
Renaissance Technologies
New York
$52.9M +$1.84M +110,700 +4%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$33.8M +$314K +18,848 +1%
State Street
6
State Street
Massachusetts
$27.5M +$3.03M +182,132 +13%
VNIM
7
Vaughan Nelson Investment Management
Texas
$25.8M +$11.6M +696,675 +91%
Norges Bank
8
Norges Bank
Norway
$22.4M
SFM
9
Systematic Financial Management
New Jersey
$20.2M -$41.2K -2,478 -0.2%
PP
10
Prudential plc
United Kingdom
$18.4M
Geode Capital Management
11
Geode Capital Management
Massachusetts
$14.8M +$345K +20,726 +3%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$12.4M +$131K +7,892 +1%
Northern Trust
13
Northern Trust
Illinois
$10.5M +$610K +36,643 +7%
Charles Schwab
14
Charles Schwab
California
$9.79M +$1.62M +97,133 +21%
Ameriprise
15
Ameriprise
Minnesota
$8.73M +$1.67M +100,506 +25%
Invesco
16
Invesco
Georgia
$8.59M -$10M -600,904 -55%
Morgan Stanley
17
Morgan Stanley
New York
$8.26M -$2.59M -155,809 -25%
Goldman Sachs
18
Goldman Sachs
New York
$7.45M +$2.96M +177,792 +72%
Wells Fargo
19
Wells Fargo
California
$6.92M +$260K +15,646 +4%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$6.78M +$7.77K +467 +0.1%
PPA
21
Parametric Portfolio Associates
Washington
$6.39M +$166K +9,982 +3%
Principal Financial Group
22
Principal Financial Group
Iowa
$6.27M -$48K -2,883 -0.8%
MAM
23
Martingale Asset Management
Massachusetts
$5.84M +$631K +37,900 +13%
JP Morgan Chase
24
JP Morgan Chase
New York
$4.69M -$562K -33,778 -11%
Man Group
25
Man Group
United Kingdom
$3.98M +$246K +14,764 +7%

VIVO Hedge Fund Activity: Q1 2019 in Review

183 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q1 2019, worth a combined $701M — up 1.6% from $690M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of VIVO and 18 opened new positions — a net loss of 7 holders — while 46 trimmed existing stakes and 80 added.

The largest buyer was Vaughan Nelson Investment Management, adding an estimated $11.6M. The largest seller was Invesco, cutting an estimated $10M.

  • 183 institutional investors held Meridian Bioscience Inc (VIVO) as of Q1 2019, down from 191 in Q4 2018.
  • Funds reported $701M of Meridian Bioscience Inc stock for Q1 2019, up 1.6% quarter-over-quarter.
  • 18 funds opened new Meridian Bioscience Inc positions in Q1 2019 and 25 closed out, a net change of -7 holders.
  • The largest Meridian Bioscience Inc buyer in Q1 2019 was Vaughan Nelson Investment Management, an estimated $11.6M added.
  • The largest Meridian Bioscience Inc seller in Q1 2019 was Invesco, an estimated $10M sold.

Based on aggregated 13F filings for Q1 2019.